Skip to main content

Healthy Subjects (HS)

7
Pipeline Programs
5
Companies
9
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
7
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 7 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Sunshine Biopharma
Sunshine BiopharmaQC - Varennes
4 programs
4
626Phase 11 trial
627Phase 12 trials
SSS17Phase 11 trial
[14C]SSS17Phase 11 trial
Active Trials
NCT06674525Recruiting50Est. Oct 2025
NCT07507513Not Yet Recruiting288Est. Dec 2029
NCT07065136Not Yet Recruiting108Est. Sep 2026
+2 more trials
Insilico Medicine
Insilico MedicineChina - Hong Kong
1 program
1
ISM8969 tablets or placeboPhase 11 trial
Active Trials
NCT07581431Not Yet Recruiting100Est. Mar 2027
Otsuka
OtsukaJapan - Tokushima
1 program
1
SibeprenlimabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT07105124Completed24Est. Feb 2023
Wockhardt
WockhardtNJ - Parsippany
1 program
1
zidebactam administered as a 1gPhase 11 trial
Active Trials
NCT07247942Completed8Est. Jan 2019
GE HealthCare
1 program
DaTSCAN™ IoflupanePHASE_11 trial
Active Trials
NCT04564092Completed9Est. Sep 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Sunshine Biopharma627
Insilico MedicineISM8969 tablets or placebo
Sunshine Biopharma627
Sunshine Biopharma[14C]SSS17
Sunshine BiopharmaSSS17
Sunshine Biopharma626
OtsukaSibeprenlimab
GE HealthCareDaTSCAN™ Ioflupane
Wockhardtzidebactam administered as a 1g

Clinical Trials (9)

Total enrollment: 629 patients across 9 trials

The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UC

Start: Mar 2026Est. completion: Dec 2029288 patients
Phase 2Not Yet Recruiting
NCT07581431Insilico MedicineISM8969 tablets or placebo

Study Evaluating ISM8969 in Healthy Adult and Elderly Participants and Obese Adult Participants at Risk of Cardiovascular Disease

Start: May 2026Est. completion: Mar 2027100 patients
Phase 1Not Yet Recruiting

Evaluation of 627 in Healthy Adult Subjects

Start: Jul 2025Est. completion: Sep 2026108 patients
Phase 1Not Yet Recruiting

A Phase 1 Mass Balance Study of [¹⁴C]SSS17 in Healthy Chinese Males

Start: Jun 2025Est. completion: Jul 20256 patients
Phase 1Not Yet Recruiting

A Study Evaluating the Food Effect on the Pharmacokinetics of SSS17 Capsules in Chinese Healthy Subjects

Start: Mar 2025Est. completion: May 202536 patients
Phase 1Completed

Evaluation of 626 in Healthy Adult Subjects

Start: Dec 2024Est. completion: Oct 202550 patients
Phase 1Recruiting
NCT07105124OtsukaSibeprenlimab

Safety and Tolerability, and PK of Sibeprenlimab in Chinese Healthy Subject

Start: Oct 2022Est. completion: Feb 202324 patients
Phase 1Completed
NCT04564092GE HealthCareDaTSCAN™ Ioflupane

A Study to Evaluate the Safety, Biodistribution, Internal Radiation Dosimetry, and Effective Dose of DaTSCAN™ Ioflupane (123I) Injection in Chinese Healthy Volunteers.

Start: May 2021Est. completion: Sep 20219 patients
Phase 1Completed
NCT07247942Wockhardtzidebactam administered as a 1g

Study of the Metabolism and Excretion of Zidebactam (WCK 5107) Following a Single Intravenous Infusion.

Start: Dec 2017Est. completion: Jan 20198 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 629 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Healthy Subjects (HS) | Pipeline & Competitive Landscape | Formulate